These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma]. Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV Vopr Onkol; 2002; 48(6):668-72. PubMed ID: 12530261 [TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
4. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D; Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400 [TBL] [Abstract][Full Text] [Related]
5. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B; Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635 [TBL] [Abstract][Full Text] [Related]
6. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850 [TBL] [Abstract][Full Text] [Related]
9. [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma]. Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV Vopr Onkol; 2004; 50(6):726-8. PubMed ID: 15755073 [TBL] [Abstract][Full Text] [Related]
10. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]
11. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089 [TBL] [Abstract][Full Text] [Related]
12. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714 [TBL] [Abstract][Full Text] [Related]
13. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081 [TBL] [Abstract][Full Text] [Related]
14. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. Milpied N; Deconinck E; Gaillard F; Delwail V; Foussard C; Berthou C; Gressin R; Lucas V; Colombat P; Harousseau JL; N Engl J Med; 2004 Mar; 350(13):1287-95. PubMed ID: 15044639 [TBL] [Abstract][Full Text] [Related]
15. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401 [TBL] [Abstract][Full Text] [Related]
16. [Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease]. Uss AL; Zmachinskiĭ VA; Milanovich NF; Skriagin AE; Dziuba EV; Vlasenkova SV; Solov'eva NS; Batan ZE; Mitskevich PB; Zavgorodniaia IL; Aleĭnikova OV; Zhavrid EA Vopr Onkol; 2000; 46(5):619-23. PubMed ID: 11202200 [TBL] [Abstract][Full Text] [Related]
17. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Linch DC; Yung L; Smith P; Maclennan K; Jack A; Hancock B; Cunningham D; Hoskin P; Qian W; Holte H; Boesen AM; Grigg A; Browett P; Trneny M Br J Haematol; 2010 Apr; 149(2):237-43. PubMed ID: 20201949 [TBL] [Abstract][Full Text] [Related]
18. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma]. Yamane T; Hino M; Ohta K; Koh KR; Nakamae H; Aoyama Y; Ota T; Kishida T; Mugitani A; Sannomiya Y; Kamitani T; Takubo T; Tatsumi N Gan To Kagaku Ryoho; 2000 Sep; 27(10):1547-55. PubMed ID: 11016000 [TBL] [Abstract][Full Text] [Related]
19. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases]. Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837 [TBL] [Abstract][Full Text] [Related]
20. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]